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Abstract 
Background: Myocardial energetic efficiency (MEE), is a strong predictor of CV events in hypertensive patient and 
is reduced in patients with diabetes and metabolic syndrome. We hypothesized that severity of insulin resistance (by 
HOMA-IR) negatively influences MEE in participants from the Strong Heart Study (SHS).
Methods: We selected non-diabetic participants (n = 3128, 47 ± 17 years, 1807 women, 1447 obese, 870 hyper-
tensive) free of cardiovascular (CV) disease, by merging two cohorts (Strong Heart Study and Strong Heart Family 
Study, age range 18–93). MEE was estimated as stroke work (SW = systolic blood pressure [SBP] × stroke volume 
[SV])/“double product” of SBP × heart rate (HR), as an estimate of  O2 consumption, which can be simplified as SV/HR 
ratio and expressed in ml/sec. Due to the strong correlation, MEE was normalized by left ventricular (LV) mass (MEEi).
Results: Linear trend analyses showed that with increasing quartiles of HOMA-IR patients were older, more likely 
to be women, obese and hypertensive, with a trend toward a worse lipid profile (all p for trend < 0.001), progressive 
increase in LV mass index, stroke index and cardiac index and decline of wall mechanics (all p < 0.0001). In multivari-
able regression, after adjusting for confounders, and including a kinship coefficient to correct for relatedness, MEEi 
was negatively associated with HOMA-IR, independently of significant associations with age, sex, blood pressure, lipid 
profile and central obesity (all p < 0.0001).
Conclusions: Severity of insulin resistance has significant and independent negative impact on myocardial mech-
ano-energetic efficiency in nondiabetic individual from a population study of American Indians.
Trial registration number NCT00005134, Name of registry: Strong Heart Study, URL of registry: https ://clini caltr ials.
gov/ct2/show/NCT00 00513 4, Date of registration: May 25, 2000, Date of enrolment of the first participant to the trial: 
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Background
Left ventricular (LV) work can be represented dimen-
sionally by the force needed to eject blood (stroke vol-
ume, SV) into the aorta, and estimated as stroke work 
(SW), the product of peak-systolic pressure times SV. 
Cuff systolic blood pressure (SBP) may be used as a sur-
rogate of peak-systolic pressure, under the assumption 
that the kinetic energy is negligible at least in resting con-
ditions. Thus, at rest, SW may be effectively estimated 
using fully non-invasive methods.
Energy to support cardiac work is provided almost 
exclusively by aerobic oxidation of substrate, with close 
coupling between myocardial oxygen consumption 
 (MVO2) and LV structure and function [1]. Thus, the 
efficiency of the left ventricle in pumping blood into the 
arterial tree (LV pump performance) may be defined as 
the ratio between the developed external work (i.e. SW) 
and the amount of energy produced for each contraction 
[2].
The energy produced by cardiomyocytes is not entirely 
converted into external power. Under normal conditions, 
the proportion of produced energy that is used for con-
traction is approximately 25%, and the residual energy is 
mainly dissipated as heat [3]. The ratio between external 
work delivered by cardiomyocytes and the amount of 
total energy produced at each beat is, therefore, a meas-
ure of myocardial mechano-energetic efficiency (MEE).
We developed a simple method for non-invasive, ultra-
sound-guided estimation of myocardial mechano-ener-
getic efficiency per gram of LV mass (MEEi), which has 
been prognostically validated [4, 5]. Low levels of MEEi 
predict increased incidence of composite cardiovascular 
events in a large hypertensive population from an open 
registry in the Campania district in Southern Italy [5] and 
are associated with high prevalence of obesity and dia-
betes. At this time, however, there is no information on 
whether increasing insulin-resistance is a factor compro-
mising MEEi, which can at least in part explain the asso-
ciation with CV morbidity [6].
Accordingly, in this analysis, we tested the hypoth-
esis that MEEi progressively deteriorates for increasing 
degrees of insulin resistance.
Methods
Population sample
We selected non diabetic participants (i.e. no history 
of diabetes and plasma glucose < 126  mg/dl) from the 
Strong Heart Study (SHS) initial cohort (2nd exam) and 
the Strong Heart Family Study (SHFS) cohort (4th exam, 
age range 18–93), with available data on fasting glucose 
and fasting insulin levels, and free of prevalent CV dis-
ease, as already done in a previous study [7]. Detailed 
descriptions of the study design and methods of the SHS 
and SHFS have previously been reported [8–10]. Obesity 
was classified as BMI ≥ 30  kg/m2. Arterial hypertension 
was defined by BP ≥ 140/90 mmHg or current antihyper-
tensive treatment.
Measurements
Fasting plasma glucose, lipid profile and other laboratory 
variables were measured by standard methods, as previ-
ously reported [8, 9, 11]. Degree of insulin resistance was 
assessed using HOMA-IR [12]. Glomerular filtration rate 
(GFR) was estimated by the simplified Modification of 
Diet in Renal Disease formula [13].
Echocardiograms were performed using phased-array, 
commercially available echocardiographs, with M-mode, 
two-dimensional and Doppler capabilities, and read 
off line using working stations equipped with frame-
grabber to measure on stop-frame images, as previously 
reported in detail [10]. LV mass, and LV mass index (by 
normalization for height in  m2.7) were estimated [10, 
14]. Relative wall thickness was computed as a dimen-
sionless ratio between posterior wall thickness and LV 
internal radius, as the measure of LV concentricity [15]. 
Stroke volume (SV) was calculated as the difference 
between LV end-diastolic and end-systolic volumes by 
the z-derived method, and allometrically normalized by 
height [16]. Cardiac output was calculated by SV times 
heart rate and allometrically normalized by height [16]. 
Ejection fraction and midwall shortening were calculated 
as previously reported [17]. To estimate MEE,  MVO2 was 
approximated using the “double product” of heart rate 
(HR) times SBP. SW was estimated as SBP × SV. Accord-
ingly, MEE is the ratio between the SW and  MVO2. Thus:
were HR can be expressed in seconds, as the time of one 
cardiac cycle (HR/60). Thus, MEE could be measured as 
the ideal amount of blood pumped by one single heart 
beat in 1  s. However, as we have previously shown, this 
amount is strictly related to the amount of myocardium 
available for pump performance [4]. Thus, ratiometric 
normalization of MEE for LV mass (MEEi) provides the 
estimate of the ideal amount of blood pumped by each 
gram of LV mass in 1 s [4, 5].
Statistics
The population sample was divided into quartiles of 
HOMA-IR and exploratory statistics were performed to 
analyse the linear trend among the different degrees of 
insulin resistance for age, sex, heart rate, blood pressure, 
BMI, risk profile (including obesity, lipid profile, kidney 
function), and LV structural and functional parameters 
MEE =
SW
MVO2
=
SBP× SV
SBP×HR
=
SV
HR
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(LV mass index and relative wall thickness, stroke index, 
cardiac index and ejection fraction). ANCOVA was used 
to study the correlation of MEEi with HOMA-IR, adjust-
ing for age, sex, obesity and hypertension. Because in 
this population, including members of the SHFS cohort, 
the level of family relatedness could be significant [18], 
we also adjusted analysis for a standard kinship coef-
ficient, based on the level of relatedness within family, 
as previously reported [19]. Continuous variables were 
used to model independent correlates of MEEi, includ-
ing HOMA-IR, kinship coefficient, age, sex, systolic BP, 
plasma cholesterol, triglycerides, waist circumference 
and two markers of inflammation, fibrinogen and PAI-
1. A two-tailed p value < 0.05 was taken as statistically 
significant.
Results
The study population comprised 3128 non-diabetic par-
ticipants (age 47 ± 17  years, 1807 women, 1447 obese, 
870 hypertensives). Table  1 shows that with increasing 
HOMA-IR patients were older, more likely to be women, 
obese and hypertensive (all p for trend < 0.001). There 
was also a clear trend toward a progressive increase in 
blood pressure and heart rate and worse lipid profile with 
increasing HOMA-IR (all p for trend < 0.001).
Whereas no effect was observed in ejection fraction, 
increasing in HOMA-IR was associated with progressive 
increase in LV mass index, stroke index and cardiac index 
and decline of midwall shortening (all p < 0.0001) (Fig. 1 
and Additional file  1: Table  S1). After adjusting for the 
kinship coefficient, age, sex, obesity and hypertension, 
MEEi progressively decreased with increasing HOMA-IR 
(Fig. 2).
In sequential multivariable regression models, the cor-
relation of MEEi with HOMA-IR was adjusted for many 
potential covariates (Table  2). First, we run the model 
including family relatedness. This regression model dem-
onstrated that the negative relation between MEEi and 
HOMA-IR was independent of the significant effect of 
kinship coefficient. In the additional models by adding 
sequentially demographics, risk factors and markers of 
inflammation, HOMA-IR remained highly significant (all 
p < 0.0001).
Discussion
This study demonstrates that in non-diabetic participants 
of the SHS cohort with normal ejection fraction and free 
of prevalent CV disease, insulin resistance is a significant 
contributor of the variance of myocardial mechano-ener-
getic efficiency per gram of LV mass. The effect of insu-
lin resistance could be demonstrated to be independent 
of major CV risk factors, including hypertension, lipid 
profile and central obesity, all factors linked to metabolic 
syndrome that could mediate the direct relation between 
insulin resistance and myocardial energetic efficiency 
[20]. This is a novel finding, consistent with the evidence 
that MEEi is emerging as a potent marker of CV risk [5].
In a normal myocardium, 60–70% of energy is pro-
duced by fatty acid oxidation, while only 30–40% of 
energy is produced by glucose-pyruvate oxidation. There 
are major differences between the two pathways [21]. 
One molecule of fatty acid produces 105 molecules of 
ATP using 46 atoms of  O2. In contrast, one molecule 
of glucose produces only 31 ATPs but using only 12 
atoms of  O2. Thus, the ratio of produced ATP/MVO2 is 
higher with glucose (P/O = 2.58) than with fatty acids 
(P/O = 2.28), which produces a redundant number of 
ATP molecules, a source of energy that is mainly dissi-
pated as heat [22, 23].
Accordingly, myocardial mechano-energetic efficiency 
is much higher when utilizing glucose than with fatty 
acids. In the diseased heart, there is in fact a progres-
sive shift toward more glucose utilization up to a near 
total utilization in heart failure, to realize the most effi-
cient energetic mechanisms in conditions of distress [23]. 
According to the described scenario, the consequence 
of insulin resistance at the myocardial level is the incon-
venient enhancement of fatty acid oxidation to maintain 
Table 1 Demographics and  metabolic risk profile 
in quartiles of HOMA-IR
*p for linear trend < 0.01
† p for trend < 0.001
≤ 1.71
(n = 784)
1.72–2.75
(n = 776)
2.76–4.66
(n = 785)
≥ 4.67
(n = 783)
Age (years)* 44 ± 18 46 ± 18 48 ± 16 48 ± 16
Sex (% women)† 52 58 59 62
Hypertension (%)† 18 28 31 35
Obesity (%)† 12 37 58 78
Body mass index (kg/
m2)†
25 ± 4 29 ± 5 31 ± 5 35 ± 7
Waist circumference 
(cm)†
88 ± 12 99 ± 12 103 ± 13 113 ± 15
Systolic BP (mmHg)† 119 ± 18 122 ± 17 124 ± 16 126 ± 17
Diastolic BP (mmHg)† 72 ± 11 75 ± 11 76 ± 10 77 ± 10
Heart rate (bpm)† 67 ± 11 68 ± 11 69 ± 11 70 ± 11
GFRMDRD (ml/
min/1.73 m2)*
94 ± 27 92 ± 25 92 ± 47 93 ± 27
Cholesterol (mg/dl)* 181 ± 38 190 ± 38 192 ± 37 185 ± 36
HDL-c (mg/dl)† 55 ± 17 50 ± 15 46 ± 13 42 ± 12
Triglycerides (mg/dl)† 105 ± 55 139 ± 87 161 ± 92 166 ± 105
Fibrinogen (mg/dl)† 335 ± 70 348 ± 74 360 ± 76 367 ± 77
PAI-1 (ng/ml)† 40 ± 47 48 ± 36 57 ± 40 71 ± 47
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energy production. Experiments in rats [24–26] and evi-
dence in humans [27] confirm this shift toward fatty acid 
metabolism. This shift is deleterious especially in patho-
logical conditions, when the natural energy provider 
should be glucose/lactate oxidation [23, 28]. In addition, 
increased fatty acid utilization promotes synthesis of pro-
teins that alter mitochondrial mechanism, resulting in 
more energy dissipated as heat [29].
Taken together, our findings support the assumption 
that mechanisms of production and delivery of energy 
play substantial role in the evolution of at least some clin-
ical manifestation of overt CV disease.
Compared to our indirect approach, a direct measure 
of myocardial metabolism would be desirable. However, 
direct detection of myocardial energetic metabolism is 
not feasible on epidemiological scale. The approach we 
use to estimate myocardial mechano-energetic efficiency 
has a strong rationale. Systolic work at each cardiac beat 
(stroke work) is represented as the area of the pressure–
volume loop (Fig.  3). As can be seen in the figure, this 
area can be approximated by a dimensionless rectangle 
having for base the volume variation (i.e. stroke volume) 
and for height the peak-systolic pressure. This calculation 
has been done, invasively validated and largely adopted 
[30], and should be considered well representative of 
LV external systolic work. The pressure volume loop 
also helps explaining the efficacy of the double product 
to estimate  MVO2 [31, 32]. A substantial part of  MVO2 
is devoted to the development of isovolumic tension 
that alters geometry of elastic elements before ejection. 
The isovolumic activity, therefore, do not develop any 
real physical work, while dissipating energy. This part of 
energy waste increases with increasing heart rate, mainly 
due to the increased frequency of isovolumic contrac-
tion, while it is reduced if cardiac output is sustained by 
stroke volume. With the energetic sparing obtained by 
Fig. 1 LV geometry, systolic function and performance in quartiles of HOMA-IR
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increasing stroke volume, if aortic pressure increases, 
end-systolic wall tension also increases, and energy dissi-
pation also increases. For these reasons, product of heart 
rate by systolic pressure is a potent and reliable predic-
tor of  MVO2 [33]. Despite the strong pathophysiological 
rationale reported above, the estimation of myocardial 
 O2 with the double product might be imprecise, espe-
cially in conditions of acute hemodynamic manipulations 
[34, 35], but it seems more reliable in steady-state condi-
tions [36].
In our analysis, MEEi progressively declines with 
increasing levels of insulin-resistance, a relation that is 
maintained also after multiple adjustments for potential 
confounders. This result was expected. We had already 
seen that in the treated hypertensive patients of the Cam-
pania Salute Network registry [20], metabolic syndrome 
and type 2 diabetes were associated with lower levels of 
Fig. 2 Least square means of MEEi for quartiles of HOMA-IR (insulin resistance), after adjusting for family relatedness, age, sex, obesity and 
hypertension. MEEi progressively decreases with increasing HOMA-IR
Table 2 Models of  multiple linear regression between  HOMA-IR and  MEEi, adjusting for  kinship coefficient 
and subsequently for age and sex, risk factors and finally markers of inflammation
BP blood pressure
Adjusted for kinship 
coefficient
+Adjusted for age and sex +Adjusted for CV risk 
factors
+Adjusted for markers 
of inflammation
Standardized 
β-coefficients
p≤ Standardized 
β-coefficients
p≤ Standardized 
β-coefficients
p≤ Standardized 
β-coefficients
p≤
Kinship coefficient 0.295 0.0001 0.069 0.003 0.079 0.0001 0.087 0.0001
HOMA-IR − 0.166 0.0001 − 0.176 0.0001 − 0.078 0.0001 − 0.070 0.0001
Age (years) − 0.342 0.0001 − 0.236 0.0001 − 0.239 0.0001
Sex (M/F) 0.155 0.0001 0.130 0.0001 0.144 0.0001
Systolic BP (mmHg) − 0.151 0.0001 − 0.151 0.0001
Cholesterol (mg/dl) − 0.037 0.055 − 0.039 0.042
Triglycerides (mg/dl) − 0.042 0.025 − 0.034 0.069
Waist circumference (cm) − 0.196 0.0001 − 0.156 0.0001
GFRMDRD (ml/min/1.73 m
2) 0.013 0.462 0.016 0.357
Fibrinogen (mg/dl) − 0.077 0.0001
PAI-1 (ng/ml) − 0.075 0.0001
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MEEi, with the worst performance found when diabetes 
and metabolic syndrome coexisted. The hypothesis that 
insulin resistance could be the reason was near obvious 
and, interestingly, we could confirm this hypothesis in 
the non-diabetic population-based cohort of the SHS. 
Studies on substrate utilization performed with Posi-
tron Emission Tomography document that insulin resist-
ance in diabetes and obesity is in fact associated with 
increased fatty acid utilization [37], thus substantially 
reducing the ratio between high energy phosphate pro-
duction and number of  O2 used [21–23], consistent with 
our clinical evidence of a reduced mechanical energetic 
efficiency with progressing degrees of insulin resistance. 
Interestingly this energetic mismatch is also demon-
strated in type 1 diabetes [38], providing additional direct 
evidence for the role of insulin.
There is a large number of studies demonstrating a link 
between insulin resistance and non-ischemic cardiomyo-
pathy or even heart failure [39, 40]. In another analysis 
in the SHS cohort, using acute myocardial infarction as a 
competing risk event, we found that the hazard of heart 
failure with type 2 diabetes was even higher than with 
arterial hypertension [41]. Despite the presence of many 
cardiovascular characteristics associated with incident 
heart failure, diabetes remained a potent determinant of 
risk of heart failure, indicating that non-hemodynamic 
characteristics participate to the biological profile at risk 
of heart failure [42]. Our study suggests that abnormal-
ity of mechanisms of production of energy related to 
insulin-resistance might be an important link to explain 
evolution toward heart failure. Interestingly, in the pres-
ence of increasing insulin resistance, increase in LV mass 
is more evident than increase in stroke volume. As docu-
mented in many previous studies, in the presence of nor-
mal LV systolic function at the chamber level, variations 
of LV mass tend to parallel variations of stroke volume 
[15, 43], because of a coherent increase in wall thick-
ness and chamber volume. In our case, this parallelism 
is altered by the greater increase in wall thickness than 
in LV chamber dimension, as documented by the pro-
gressive increase in relative wall thickness, and in heart 
rate. From the hemodynamic standpoint, this plot makes 
understandable why progressive insulin-resistance paral-
lels increased  O2 consumption without a corresponding 
Fig. 3 Pressure–volume loop with the indication of the different steps of cardiac cycle, starting with end-systolic volume and the lowest cavity 
pressure. Cardiac activity proceeds counterclockwise. Stroke work is the area of the loop than can be approximated as a dimensionless rectangle 
area with the basis represented by stroke volume and the height by peak-systolic pressure. The grey area is the potential energy developed
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increased LV pump performance, therefore decreasing 
myocardial energetic efficiency.
Also, consistent with our findings, insulin resist-
ance has also been reported to be associated with other 
adverse characteristics of CV system, including diastolic 
dysfunction [44] and increased arterial stiffness [45]. In 
addition to the impaired regulation of substrate metabo-
lism and delivery, other mechanisms are also involved in 
the association of insulin resistance with incident CV dis-
ease, including alterations of signal transduction [6].
Conclusion
The present study demonstrated that myocardial ener-
getic efficiency is affected by the level of insulin resist-
ance in non-diabetic participants from the SHS. Patients 
with high insulin-resistance have low amount of blood, 
ejected at each systole, per gram of LV mass, indepen-
dently of common confounders such as hypertension, 
waist circumference and markers of inflammation.
Additional file
Additional file 1: Table S1. LV geometry, systolic function and perfor-
mance in quartiles of HOMA-IR.
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